St. Gallen (Switzerland)
All products of Vifor Pharma for treatment of iron deficiency were discovered, developed and produced in St. Gallen. From 1999 to 2010 the Galenica Group invested around 100 million CHF in the modernization of the facilities and the expansion of the R&D and production capacities. Two drug discovery projects are presently being pursued in these facilities, equipped with state-of-the-art infrastructure. Another product – an iron-based phosphate binder – was discovered, developed, and material for the phase three clinical trial is now being produced at the St. Gallen site.
From 2008 to 2010, between 1.4 and 2.1 tons of active iron ingredients were produced every day (about 500–700 batches per year). In the last few years – most recently in spring 2010 – the site has been inspected by the US Food and Drug Administration (FDA). The Swiss agency for the authorisation and supervision of therapeutic products – Swissmedic – inspects the site every two years.
OM Pharma develops immunomodulators of synthetic and biologic origin and studies their mode of action with focus on the receptors of the innate immune system. Geneva also contributes to the synthesis of new iron ligands.
A new production plant, inaugurated in 2005, produces more than five tons of lyophilized biological active pharmaceutical ingredients and 110 millions of capsules of Broncho-Vaxom® and Uro-Vaxom® each year. The site is certified ISO9001 and 14001 as well as regulary inspected by Swissmedic.
Fribourg (Villars-sur-Glane)/Ettingen (Switzerland)
Pharmaceutical production and additional development activities are located in Fribourg (Villars-sur-Glane) and Ettingen. A team of chemists, pharmacists and lab technicians is specialized in the pharmaceutical and analytical development of new products and formulations for both Vifor Pharma and third parties (contract development). Special focus is on laboratory and pilot batches, stability studies, analytical method development or on process validation.
At the Vifor Pharma headquarters in Glattbrugg, near Zurich, clinical trials are planned and supervised and all pharmacovigilance activities are coordinated. The global clinical development activities in Glattbrugg are focused on the iron replacement products Ferinject®, Venofer®, and Maltofer® and on the phosphate binder Velphoro®. Vifor Pharma fosters an environment that encourages collaboration. For each product, multidisciplinary teams are set up with highly skilled specialists, who are responsible for planning, implementation, analysis and reporting of the clinical development activities. The health of patients is always at the heart of what we do and that is why, throughout the entire clinical lifecycle of our products, safety experts are intimately involved in these cross-functional teams.
The company’s R&D hub in Victoria, Canada, is responsible for the clinical development activities for CellCept® in autoimmune diseases, and in the clinical development of Velphoro®, a new iron-based phosphate binder.